{{Rsnum
|rsid=11164838
|Gene=FAM69A
|Chromosome=1
|position=92929821
|Orientation=plus
|GMAF=0.4408
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FAM69A
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 34.5 | 47.8 | 17.7
| HCB | 5.8 | 32.1 | 62.0
| JPT | 8.0 | 31.0 | 61.1
| YRI | 88.4 | 10.2 | 1.4
| ASW | 66.1 | 32.1 | 1.8
| CHB | 5.8 | 32.1 | 62.0
| CHD | 7.3 | 38.5 | 54.1
| GIH | 31.7 | 41.6 | 26.7
| LWK | 86.4 | 13.6 | 0.0
| MEX | 29.3 | 51.7 | 19.0
| MKK | 87.7 | 11.0 | 1.3
| TSI | 23.5 | 52.9 | 23.5
| HapMapRevision=28
}}[[rs11164838]] has been reported in a large study to be associated with [[multiple sclerosis]].

The risk allele (oriented to the dbSNP entry) is (C); the odds ratio associated with this allele is 1.12 (CI 1.05-1.18). {{PMID|17660530}}

{{PharmGKB
|RSID=rs11164838
|Name_s=
|Gene_s=FAM69A
|Feature=
|Evidence=PubMed ID:17660530
|Annotation=In a replicated GWAS of U.K. and U.S. case/parent trios, this variant was shown to be associated with multiple sclerosis risk.
|Drugs=
|Drug Classes=
|Diseases=Multiple Sclerosis
|Curation Level=Curated
|PharmGKB Accession ID=PA162356167
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11164838
|overall_frequency_n=44
|overall_frequency_d=128
|overall_frequency=0.34375
|n_genomes=27
|n_genomes_annotated=0
|n_haplomes=38
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}